Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
5.10
+0.27 (5.59%)
At close: Sep 26, 2025, 4:00 PM EDT
5.13
+0.03 (0.59%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Vanda Pharmaceuticals Employees
Vanda Pharmaceuticals had 368 employees as of December 31, 2024. The number of employees increased by 165 or 81.28% compared to the previous year.
Employees
368
Change (1Y)
165
Growth (1Y)
81.28%
Revenue / Employee
$552,899
Profits / Employee
-$181,894
Market Cap
301.35M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 368 | 165 | 81.28% |
| Dec 31, 2023 | 203 | -87 | -30.00% |
| Dec 31, 2022 | 290 | 12 | 4.32% |
| Dec 31, 2021 | 278 | -14 | -4.79% |
| Dec 31, 2020 | 292 | 8 | 2.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VNDA News
- 2 days ago - Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial" - PRNewsWire
- 4 weeks ago - Vanda: Next Phase Of Fanapt Growth Might Be With Bysanti Advancement - Seeking Alpha
- 4 weeks ago - Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences - PRNewsWire
- 4 weeks ago - Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera - PRNewsWire
- 5 weeks ago - Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz® - PRNewsWire
- 5 weeks ago - In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results - PRNewsWire